X Bioscience PCL (BKK:XBIO)
Thailand · Delayed Price · Currency is THB 0.0700
0.00 (0.00%)
At close: Sep 3, 2026
X Bioscience PCL Ratios and Metrics
Market cap in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 851 | 179 | 1,030 | 732 | 1,612 | 3,532 | |
Market Cap Growth | 4.07% | -82.67% | 40.78% | -54.60% | -54.38% | 7.16% |
Enterprise Value | 1,038 | 521 | 1,408 | 1,116 | 2,451 | 3,856 |
Last Close Price | 0.07 | 0.09 | 0.86 | 1.15 | 3.21 | 7.03 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 4.01 | 1.38 | 3.23 | 2.35 | 4.68 | 13.91 |
PB Ratio | 2.38 | 0.80 | 1.25 | 4.00 | 15.72 | 5.25 |
P/TBV Ratio | 3.89 | 7.98 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.88 | 4.02 | 4.41 | 3.58 | 7.11 | 15.18 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.36 | 1.08 | 0.43 | 2.27 | 4.61 | 0.70 |
Debt / EBITDA Ratio | - | - | - | - | - | 25.74 |
Net Debt / Equity Ratio | 0.35 | 1.06 | 0.37 | 2.12 | 4.46 | 0.66 |
Net Debt / EBITDA Ratio | -0.17 | -0.54 | -1.37 | -3.78 | -2.41 | -32.63 |
Net Debt / FCF Ratio | -0.35 | -2.99 | -5.59 | -2.91 | -1.57 | -2.08 |
Asset Turnover | 0.27 | 0.13 | 0.30 | 0.43 | 0.34 | 0.20 |
Inventory Turnover | 24.32 | 10.88 | 19.39 | 16.08 | 7.15 | 4.58 |
Quick Ratio | 0.27 | 0.05 | 0.21 | 0.13 | 0.07 | 0.11 |
Current Ratio | 1.30 | 0.93 | 0.25 | 0.17 | 0.12 | 0.22 |
Return on Equity (ROE) | -180.44% | -86.14% | -51.88% | -103.40% | -85.26% | -12.32% |
Return on Assets (ROA) | -59.97% | -28.06% | -14.58% | -10.46% | -17.52% | -4.83% |
Return on Invested Capital (ROIC) | -155.64% | -57.04% | -29.47% | -21.30% | -33.84% | -9.06% |
Return on Capital Employed (ROCE) | -203.50% | -160.20% | -25.60% | -38.50% | -116.60% | -11.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -84.41% | -262.59% | -25.26% | -20.16% | -35.74% | -7.83% |
FCF Yield | -41.34% | -44.18% | -5.32% | -18.26% | -18.07% | -6.02% |
Buyback Yield / Dilution | -216.98% | -118.20% | -46.88% | -7.78% | - | -19.79% |